PDS Biotech's Triplet Therapy Shows Clinical Activity In Advanced HPV-Associated Malignancies

  • PDS Biotechnology Corporation PDSB has announced the publication of an abstract by the American Society of Clinical Oncology summarizing interim data from the National Cancer Institute (NCI)-led Phase 2 trial evaluating a combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ relapsed or refractory advanced cancer.
  • Data will be presented at the 2021 ASCO Annual Meeting and is expected to include results from a larger sample than the 14 patients included in the abstract.
  • Fourteen patients with advanced HPV 16+ cancers (5 cervical, 2 vaginal/vulvar, 4 anal, 3 oropharyngeal) were treated.
  • 10/14 (71%) patients have had objective responses, including 1 complete response (anal cancer) and 9 partial responses (3 cervical, 2 vulvar/vaginal, 2 anal, 2 oropharyngeal), with 9/10 of these responses ongoing after a median of 5 months of follow up.
  • 4/14 (28.6%) patients had severe treatment-related toxicity.
  • The triple combination demonstrated a manageable safety profile along with early evidence of notable clinical activity.
  • Chardan Capital analyst Geulah Livshits maintains a Buy and raises the price target from $10 to $11.
  • Price Action: PDSB shares are up 10.4% at $6.34 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsHealth CarePrice TargetAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!